Olink Holding AB has concluded an initial public offering on The Nasdaq Global Market, New York in the United States. The IPO involved a public offering of 20,294,116 common shares in the form of American Depositary Shares (“ADSs”), including 7,058,822 ADSs to be sold by the selling shareholders, at a price to the public of $20.00 per ADS, with each ADS representing one common share. The gross proceeds of the offering, before deducting offering expenses, amounted to $405.9 million. 

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC acted as lead book-running managers for the offering. SVB Leerink LLC acted as a joint book-running manager. BTIG, LLC acted as co-manager.

Baker McKenzie acted as legal advisor to the minority selling shareholders with a team consisting of Henric Roth, Ian Gulam and Linnea Back in Stockholm, Adam Farlow and Megan Schellinger in London, as well as additional lawyers from Baker McKenzie offices in the US. 

Explore Our Newsroom